Prior malignancy:\r\nSubjects with a history of a prior malignancy other than angiosarcoma who have been disease-free for at least  years prior to the first dose of study drug and/or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible
Has any other malignancy other than the one for which they are receiving tazemetostat Exception: Subject who has been disease-free of a prior malignancy for  years, or subject with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible.
Concurrent active malignancy; exceptions include patients who have been disease free for  years, patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, or patients with another malignancy that is indolent or definitively treated
History of or concurrent malignancy of solid tumours, except for below: Exception: Subjects who have been disease-free for  years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
Presence of other significant cancer(s) or history of other significant cancer(s) within the last  years (patients who have been cancer-free for  years, or have a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma of the cervix are eligible)
Has had a prior malignancy other than the malignancies under study - EXCEPTION: A subject who has been disease-free for  years, or a subject with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible
History of secondary malignancy or history of other malignancy within the last three years (patients who have been disease-free for three years, or have a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible)
Prior malignancy; note: subjects who have had another malignancy and have been disease-free for >  years, or subjects with a history of completely resected non-melanomatous skin carcinoma, successfully treated in situ carcinoma, or successfully treated bladder cancer are eligible
A history of other malignancy =<  years previous with the exception of non-melanoma skin cancer, any in situ cancer that has been successfully resected and cured, treated superficial bladder cancer, or any early-stage solid tumor that was successfully resected without need for adjuvant radiation or chemotherapy.
Patients with a prior diagnosis of cancer must not have received treatment in the last  years prior to registration\r\n* NOTE: Patients with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible
History of other malignancy; subjects who have been disease-free for  years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinomas are eligible
Has had a prior malignancy other than the malignancies under study Exception: Subject who has been disease-free for  years, or a subject with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
Has had a prior malignancy other than the malignancies under study Exception: A subject who has been disease-free for  years, or a subject with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible.
Other active malignancies besides NSCLC within  years prior to Screening. Exceptions: adequately treated malignancies not likely to require therapy (e.g., completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma). Subjects must be in complete remission from prior malignancy in order to be eligible to enter the study.
A history of other malignancy =<  years previous with the exception of non-melanoma skin cancer, any in situ cancer that has been successfully resected and cured, treated superficial bladder cancer, or any early-stage solid tumor that was successfully resected without need for adjuvant radiation or chemotherapy
Patients with a previous malignancy (other than the patients' known cancer) that were treated successfully and are disease-free for at least  years are allowed
Other past or current malignancy that could interfere with the interpretation of outcome; subjects who have been free of active malignancy for at least  years, or have a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, or whose malignancy will not interfere with the interpretation of study results, are eligible
Prior malignancy, unless they have been disease-free for  years, or have a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma
Concurrent malignancy; exception: Subjects who have been disease-free for  years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible; subjects with second malignancies that are indolent or definitively treated may be enrolled
History of another malignancy; exception: subjects who have been disease-free for  years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible
Patient must not have a history of other malignancy =<  year previous with the exception of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma
Other past or current solid tumor malignancy\r\n* Subjects who have been free of malignancy for at least  years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible
Prior malignancy; Note: subjects who have had another malignancy and have been disease-free for  years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible
History of another malignancy; exception: subjects who have been disease-free for  years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible
Other past or current malignancy; subjects who have been free of malignancy for at least  years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible
History of another active malignancy; Note: subjects who have had another malignancy and have been disease-free for  years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible
Prior malignancy; Note: subjects who have had another non VHL related malignancy and have been disease-free for  years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible
Prior malignancy; exception: subjects who have had another malignancy and have been disease-free for three years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible
Prior malignancy; exceptions: Subjects who have had another malignancy and have been disease free for  years or subjects with a history of completely resected non melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible
Other past or current malignancy. Subjects free of malignancy for at least  years or have history of definitively treated non-melanoma skin cancer, or successfully treated in situ carcinoma, are eligible
Other past or current malignancy; subjects who have been free of malignancy for at least  years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma (any site) are eligible; women with a history of cervical cancers are allowed
Prior malignancy. Note: Subjects who have had another malignancy and have been disease-free for  years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.
Concurrent malignancy; exceptions: patients who have been disease-free for  years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible; subjects with concurrent malignancies that are indolent or definitely treated may be enrolled
History of another malignancy with exceptions below, or any malignancy with confirmed activating RAS mutation. Exception: (a) Subjects who have been successfully treated and are disease-free for  years, (b) a history of completely resected non-melanoma skin cancer, (c) successfully treated in situ carcinoma, (d) chronic lymphocytic leukemia in stable remission, or (e) indolent prostate cancer (definition: clinical stage T or Ta, Gleason score <=, and prostate-specific antigen < nanogram per milliliter) requiring no or only anti-hormonal therapy, are eligible. Note: Prospective RAS testing is not required. However, if the results of previous RAS testing are known, they must be used in assessing eligibility.
Active malignancy other than the cancer under study. Subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.
History of another malignancy (Exception: Subjects who have been disease-free for  years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible)
Prior malignancy other than CRPC. Subjects who have been disease-free for  years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
No current malignancy; subjects who have been free of malignancy for at least  years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma (any site) are eligible; women with a history of cervical cancers are allowed
History of another malignancy. Exception: (a) Subjects who have been successfully treated and are disease-free for  years, (b) a history of completely resected non-melanoma skin cancer, (c) successfully treated in situ carcinoma, (d) CLL in stable remission are eligible.
Prior malignancy (Note: subjects who have had another malignancy and have been disease-free for  years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible).
Current or previous other malignancy within  years of study entry. Exception: Subjects who have been disease-free for  years or more, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
Current or previous other malignancy within  years prior to randomization. Subjects who have been free of malignancy for at least  years, or have a history of completely resected non-melanoma skin cancer or successfully treated carcinoma in situ, are eligible.
History of other malignancy. Subjects who have been disease-free for  years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
History of another malignancy; Note: subjects who have had another malignancy and have been disease-free for  years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible
Prior malignancy; note: subjects who have had another malignancy and have been disease-free for  years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible
Patients must not have active prior malignancy\r\n* Note: subjects who have had another malignancy and have been disease-free for  years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible